Cleveland BioLabs, Inc. (CBLI) News
Filter CBLI News Items
CBLI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CBLI News Highlights
- For CBLI, its 30 day story count is now at 7.
- Over the past 11 days, the trend for CBLI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest CBLI News From Around the Web
Below are the latest news stories about Cytocom Inc that investors may wish to consider to help them evaluate CBLI as an investment opportunity.
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via WebcastCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/. The replay of the webcast will be archived on the website for 90 days beginning at approximately 10:00 a.m. ET, on August |
Cytocom, Inc. Reports Second Quarter 2021 Financial ResultsCytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, |
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance AgreementCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research. The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll |
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business ConferenceCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021. Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on |
Cytocom, Inc. to Report Second Quarter 2021 Financial ResultsCytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m. ET, to discuss its corporate and financial results for the second quarter 2021. |
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs. |
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabsCytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. The all-stock transaction, first announced in October 2020, was formally completed on July 27, 2021. |
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt FinancingCytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital. The financing is led by a $75 million equity commitment from GEM Global Yield LLC SCS in the form of a Share Subscription Facility. Cytocom intends to draw down the first $15 million within 30 days of the closing of the recently completed merger between Cleveland BioLabs and Cytocom. A combination of |
Cytocom Inc. Announces Completed Merger with Cleveland BioLabsFORT COLLINS, Colo., July 28, 2021 /PRNewswire/ -- Cytocom Inc. ("Cytocom" or "Company"), a leading biopharmaceutical company creating next-generation therapies that focus on immune homeostasis, today announced the completion of its merger with Cleveland BioLabs, Inc. The all-stock |
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed MergerCleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that the Company and Cytocom Inc., a leading biopharmaceutical company developing next generation therapeutics that target immune restoration and homeostasis, will host an investor call and live webcast on Wednesday, July 7 at 8:30 a.m. ET. |